At the 18th European Conference on Computational Biology and the 27th Conference on Intelligent Systems for Molecular Biology, IBM will present significant, novel research that led to the implementation of three machine learning solutions aimed at accelerating and guiding cancer research.
Using microfluidic probe, IBM scientists perform microscale IHC on tissue sections with a gradient of incubation times for the primary antibody.
Our team of IBM researchers published research in Radiology around a new AI model that can predict the development of malignant breast cancer in patients within the year, at rates comparable to human radiologists.
IBM researchers launch the first in-depth, large scale study of time courses when different antibodies appear, and their correlations to type 1 diabetes.
IBM and Johns Hopkins University School of Medicine Discover Unique, Pathogenic Autoimmune Cells in Type 1 Diabetes
Researchers at JHU and IBM identify new cells involved in the autoimmune attack on insulin-producing cells in type 1 diabetes.
New continuous-flow approach to chemical synthesis holds promise in accelerating therapeutic discovery for drug-resistant infectious diseases and cancer.
New research combining the power of brain modeling, IBM’s AI, and the IBM Cloud sheds light on how brain cells interact in Huntington’s disease.
A comprehensive analysis of tumor ecosystems that represents an important step in research that may lead to precision medicine approaches to treat breast cancer.
IBM scientists use crowdsourcing and AI techniques to explore what different types of conversational laughter can tell us.
IBM Research and New York University are using AI to analyze retina imaging data and help to assess the presence of glaucoma.
New research shows that the number of mitochondria in a cell is associated with drug resistance, which could have a far-reaching impact in cancer treatment.